IL319946A - Use of a bispecific anti-CLDN4/anti-CD137 antibody in combination with a PD-1 signaling inhibitor for cancer treatment - Google Patents

Use of a bispecific anti-CLDN4/anti-CD137 antibody in combination with a PD-1 signaling inhibitor for cancer treatment

Info

Publication number
IL319946A
IL319946A IL319946A IL31994625A IL319946A IL 319946 A IL319946 A IL 319946A IL 319946 A IL319946 A IL 319946A IL 31994625 A IL31994625 A IL 31994625A IL 319946 A IL319946 A IL 319946A
Authority
IL
Israel
Prior art keywords
cldn4
bispecific antibody
cancer treatment
antibody combined
signal inhibitor
Prior art date
Application number
IL319946A
Other languages
English (en)
Hebrew (he)
Inventor
Masahito Sato
Keita Hirouchi
Aya Kikuchi
Original Assignee
Astellas Pharma Inc
Masahito Sato
Keita Hirouchi
Aya Kikuchi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Masahito Sato, Keita Hirouchi, Aya Kikuchi filed Critical Astellas Pharma Inc
Publication of IL319946A publication Critical patent/IL319946A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL319946A 2022-10-19 2023-10-18 Use of a bispecific anti-CLDN4/anti-CD137 antibody in combination with a PD-1 signaling inhibitor for cancer treatment IL319946A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022167362 2022-10-19
PCT/JP2023/037616 WO2024085166A1 (ja) 2022-10-19 2023-10-18 がん治療におけるpd-1シグナル阻害剤との組み合わせによる抗cldn4-抗cd137二重特異性抗体の使用

Publications (1)

Publication Number Publication Date
IL319946A true IL319946A (en) 2025-05-01

Family

ID=90737914

Family Applications (1)

Application Number Title Priority Date Filing Date
IL319946A IL319946A (en) 2022-10-19 2023-10-18 Use of a bispecific anti-CLDN4/anti-CD137 antibody in combination with a PD-1 signaling inhibitor for cancer treatment

Country Status (10)

Country Link
EP (1) EP4606384A1 (cg-RX-API-DMAC7.html)
JP (1) JP7730432B2 (cg-RX-API-DMAC7.html)
KR (1) KR20250089513A (cg-RX-API-DMAC7.html)
CN (1) CN119997975A (cg-RX-API-DMAC7.html)
AU (1) AU2023365438A1 (cg-RX-API-DMAC7.html)
CL (1) CL2025001156A1 (cg-RX-API-DMAC7.html)
IL (1) IL319946A (cg-RX-API-DMAC7.html)
MX (1) MX2025004457A (cg-RX-API-DMAC7.html)
TW (1) TW202426503A (cg-RX-API-DMAC7.html)
WO (1) WO2024085166A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026042803A1 (ja) * 2024-08-21 2026-02-26 アステラス製薬株式会社 がん治療におけるプラチナ系薬剤との組み合わせによる抗cldn4-抗cd137二重特異性抗体の使用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
WO2008114733A1 (ja) 2007-03-16 2008-09-25 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-4抗体
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
PL2346994T3 (pl) 2008-09-30 2022-04-19 Ablexis, Llc Myszy knock-in do wytwarzania chimerycznych przeciwciał
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
EP2707723B1 (en) 2011-05-12 2016-02-10 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
BR112015007184A2 (pt) 2012-10-02 2017-08-08 Bristol Myers Squibb Co combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer
MX380176B (es) * 2014-04-07 2025-03-12 Chugai Pharmaceutical Co Ltd Molecula ligada a antigeno inmunoactivada.
EP3064507A1 (en) * 2015-03-06 2016-09-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
RU2727165C2 (ru) 2015-05-04 2020-07-21 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Слитый полипептид с противораковой активностью
BR112018071612A2 (pt) * 2016-04-22 2019-02-19 Alligator Bioscience Ab polipeptídeos biespecíficos inovadores contra cd137
PH12022552323A1 (en) * 2020-03-31 2023-12-04 Chugai Pharmaceutical Co Ltd Claudin-6 targeting multispecific antigen-binding molecules and uses thereof
CN116133684B (zh) 2020-05-27 2025-07-18 阿里亚利斯治疗公司 抗人nr1抗体衍生物
IL307744A (en) * 2021-04-22 2023-12-01 Astellas Pharma Inc Anti-CLDN4/anti-CD137 bispecific antibody

Also Published As

Publication number Publication date
MX2025004457A (es) 2025-05-02
AU2023365438A1 (en) 2025-04-17
JPWO2024085166A1 (cg-RX-API-DMAC7.html) 2024-04-25
TW202426503A (zh) 2024-07-01
WO2024085166A1 (ja) 2024-04-25
CN119997975A (zh) 2025-05-13
JP7730432B2 (ja) 2025-08-27
CL2025001156A1 (es) 2025-05-23
EP4606384A1 (en) 2025-08-27
KR20250089513A (ko) 2025-06-18

Similar Documents

Publication Publication Date Title
IL316867A (en) Macrocyclic KRAS inhibitors for cancer treatment
EP3906061A4 (en) METHODS OF TREATMENT OF CANCER USING COMBINATIONS OF PARP INHIBITORS AND ANTIBODY RADIOCONJUGATE
IL327418A (en) RAS-PI3K inhibitors for the treatment of cancer and immunological diseases
EP4242207A4 (en) Kras inhibitors for treatment of cancers
IL285050A (en) Administering PD-1 inhibitors for the treatment of skin cancer
IL316829A (en) Menin-MLL inhibitors for cancer treatment
IL307744A (en) Anti-CLDN4/anti-CD137 bispecific antibody
CA3270683A1 (en) Use of anti-cldn4/anti-cd137 bispecific antibody combined with pd-1 signal inhibitor for cancer treatment
HUE067601T2 (hu) PD-1 inhibitorok intraléziós beadása a bõrrák kezelésére
PH12022550585A1 (en) Methods of treating cancer by the use of pd-1 axis inhibitors and anti-periostin antibodies
IL313864A (en) Methods for treating recurrent ovarian cancer using bispecific antibodies against MUC16 and against CD3 alone or in combination with antibodies against PD-1
AU2024362771A1 (en) Combination treatment of prostate cancers with two bispecific antibodies
CA3266666A1 (en) SHP-1 INHIBITORS FOR CANCER TREATMENT
CA3304766A1 (en) Methods of treating cancer by administering anti-pd-l1/anti-4-1bb bispecific antibodies
HK40088568A (en) Methods of treating cervical cancer by administering the pd-1 inhibitor antibody cemiplimab
EP4031129A4 (en) COMBINATION OF A SMALL MOLECULE INHIBITOR OF PD-1/PD-L1 INTERACTION AND ANTI-PD-1 ANTIBODIES FOR THE TREATMENT OF CANCER
CA3306323A1 (en) Anti-pd-l1 and anti-4-1bb bispecific antibody for treating tumors
CA3289052A1 (en) Use of an anti-tgf.beta.r2/pd-1 bispecific antibody to treat cancer
TW202617776A (zh) 治療smarcb1缺陷型癌症之方法
IL327531A (en) Use of anti-SIRP-alpha antibodies for cancer treatment
CA3307105A1 (en) Use of anti-sirp-alpha antibodies to treat cancer
HK40090320A (en) Treatment of cancer using a cea cd3 bispecific antibody and a tgfbeta signaling inhibitor
HK40091622A (en) Bispecific antibodies for use in treatment of nlrc4-gof inflammasomapathy
IL320200A (en) Antibodies for cancer treatment anti-BSSL
HK40096277A (en) Methods of treating cancer by administering a pd-1 inhibitor